Brief: Hansa Biopharma Q3 Total Turnover SEK 22.8 Million
26/10/2023 06:26
Oct 26 (Reuters) - Hansa Biopharma AB HNSA.ST :
* Q3 TOTAL TURNOVER AMOUNTED TO SEK 22.8 MILLION
* Q3 OPERATING PROFIT SEK 202,2 MILLION VERSUS SEK 139,5
MILLION
YEAR AGO
* OUTLOOK: EXPECTS INCREASED COMMERCIAL SALES IN Q4 AND
BEYOND
THANKS TO NEW MARKETS SUCH AS THE UK, GERMANY AND BELGIUM
Source text for Eikon: ID:nWkrc9TbDN
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS